From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
The singer-songwriter gained recognition from the Recording Academy in the early 1990s, winning the Grammy for Best New ...
Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...